Post-marketing Surveillance Study of the Saphir Stem in Primary Hip Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Alessio Vitale, Biotech
- Phone Number: +390251650371
- Email: regulatory@bioimpianti.it
Study Contact Backup
- Name: Fabio Stringhi, biomedic eng
- Phone Number: patients under guardianship or
- Email: fabio.stringhi@bioimpianti.it
Study Locations
-
-
-
Toulouse, France
- Recruiting
- Hopital Ducuing
-
Contact:
- Gerard Giordano
- Email: ortho.giordano@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients>18 years
- Candidate for primary total hip replacement with femoral stem and acetabular cup
- if ostheoarthritis patients aged 18 to 85 years
- if femoral neck fracture patients aged 18 to 90 years
- patients with social security scheme
- patients understands the condition of the study and is willing to partecipate for the duration of the clinical investigation
- patients who gavee consent to partecipare in the clinical investigation
Exclusion Criteria:
- <18 years
- if female, pregnant
- patient who has already had primary hip surgery on the same side
- local or disseminated neoplastic disease
- inability to understand the study and agree to partecipate
- patients cancelling partecipation before surgery
- patients under guardianship or curatorship
- patients without a social security scheme
- patients refusing to partecipate
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
stem survival rate
Time Frame: 1 year, 3 years, 5 and 10 years
|
Kaplan Meier survival analysis
|
1 year, 3 years, 5 and 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gerard Giordano, medicine, Hopital Ducuing
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRCS202201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.